Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Dominion Energy Inc (D) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Dominion Energy Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while Dominion Energy Inc trades at $69.88 (market cap $60.92B). The key difference: Dominion Energy Inc is far larger — about 13.6× ACADIA Pharmaceuticals Inc.'s market cap, and Dominion Energy Inc pays a 3.86% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | D | |
|---|---|---|
Market Cap | $4.49B | $60.92B |
Sector | Health | Utilities |
52-Week High | $28.06 | $69.84 |
52-Week Low | $20.06 | $56.32 |
Enterprise Value | $3.69B | $113.32B |
Dividend Yield | — | 3.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Dominion Energy (D) trades at $69.84, up 0.13% on the day, with a bullish technical signal and consistent earnings beats in recent quarters. The stock shows strong profitability with a 16.93% net income margin and trades near the analyst consensus price target of $69.50. Recent news highlights a proposed $66.8 billion acquisition by NextEra Energy, positioning Dominion as a key player in AI infrastructure and data center power demand.
The outlook remains positive due to strategic positioning in renewable energy and data center growth, though regulatory approval risks for the merger and high debt levels pose challenges. Earnings momentum and institutional support provide upside potential, but investors should monitor merger developments and interest rate impacts on utility valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Dominion Energy Inc
Based in Richmond, Virginia, Dominion Energy is an integrated energy company with over 30 gigawatts of electric generation capacity and more than 90,000 miles of electric transmission and distribution lines. Dominion owns a liquefied natural gas export facility in Maryland and is constructing a 5.2 GW wind farm off the Virginia Beach coast.
Read more on D →
